Cell Proliferation News and Research

RSS

SOX2 gene potential therapeutic target for SCLC

Expression of the Sry-related HMG box 2 gene is higher in small-celllung cancer tissue samples than in non-cancerous lung tissue samples, according to findings from a genetic study.

13 Sep 2012

Solubilized curcumin shrinks lung tumors in mice

Belgian researchers report that orally administered curcumin can reduce the size of lung cancer tumors in mice.

13 Sep 2012

Addition of sorafenib to chemotherapy does not prolong survival

The addition of sorafenib to gemcitabine/cisplatin fails to provide any additional benefit in chemotherapy-naïve patients with nonsquamous non-small-cell lung cancer, research shows.

13 Sep 2012

Wnt5a protein essential in repairing the intestine's inner lining

Scientists at Washington University School of Medicine in St. Louis have identified a protein essential to repairing the intestine's inner lining.

7 Sep 2012

DEAD-box proteins function as recycling nanopistons when unwinding RNA

AUSTIN, Texas-Molecular biologists at The University of Texas at Austin have solved one of the mysteries of how double-stranded RNA is remodeled inside cells in both their normal and disease states. The discovery may have implications for treating cancer and viruses in humans.

3 Sep 2012

Study shows molecular mechanism behind type 3c pancreatic diabetes

Mice develop pancreatic diabetes (type 3c) when they lack certain genes in the E2F group, and to understand how this happens, Olatz Zenarruzabeitia has focussed on the molecular mechanism behind it.

29 Aug 2012

Personalized colon cancer therapy based on genetics of specific cancer

University of Minnesota Medical School and Masonic Cancer Center researchers have partnered with geneticists from Genentech, Inc., to discover how some proteins may cause the development of some forms of colon cancers.

24 Aug 2012

Portable Micro-Plasma Device may help repair skin after laser surgery

A National Cheng Kung University (NCKU) research team has designed a Portable Micro-Plasma Device (PMPD) that may be the ultimate solution to repairing the skin after laser surgery.

21 Aug 2012

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Cancer may be the Harry Houdini of diseases—it often finds devious ways to escape treatment. Because cancer disables our cellular quality control mechanisms, rampant mutations that cause tumor cells to grow uncontrollably can also generate resistance to anticancer drugs. Even if 99 percent of the tumor is destroyed, that 1 percent can come roaring back. How do we knock out that 1 percent? By attacking the cancer from multiple angles, using multiple treatments and strategies.

20 Aug 2012

UCP2 uncoupling protein occurs mainly in cells of the immune system

When uncoupling proteins are active, mitochondria produce heat instead of ATP. This may be useful under certain circumstances, such as when an animal is hibernating. But non-hibernating animals also have them. Particularly poorly understood is the uncoupling protein UCP2. Elena Pohl and colleagues at the University of Veterinary Medicine, Vienna, show that the protein occurs mainly in cells of the immune system.

18 Aug 2012

Peptide combinations might offer more effective cancer therapy

Two studies suggest that two peptide agents used either together or individually with a low-dose of a standard chemotherapy drug might offer more effective cancer therapy than current standard single-drug treatments.

17 Aug 2012

CYCLOPS genes may serve as targets for cancer therapies

The genomic tumult within tumor cells has provided scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard with clues to an entirely new class of genes that may serve as an Achilles' heel for many forms of cancer.

16 Aug 2012

Combination of exercise and S-nitrosoglutathione improves recovery from stroke

In a study published in the current issue of Restorative Neurology and Neuroscience scientists report that a therapy combining exercise with the neurovascular protective agent S-nitrosoglutathione (GSNO) improved recovery from stroke in a rat model. GSNO is a compound found naturally in the body and it has no known side effects or toxicity.

16 Aug 2012

Researchers identify molecular pathway by which Notch regulates cell proliferation in lung cancer

Lung cancer is one of the most aggressive types of cancer and the most common cause of death from this disease worldwide. Despite the progress in the molecular biology of lung cancer achieved in recent years, the mechanisms used by tumor cells to grow and spread throughout the body are not yet completely understood. This lack of information is responsible for the limited range of available therapeutic possibilities and their undesirable side effects.

14 Aug 2012

Interface zone fibroblasts play key role in gastric cancer

Interface zone fibroblasts in gastric adenocarcinoma promote the invasion, migration, and proliferation of cancer cells, as well as prevent apoptosis, to a greater degree than normal or tumor zone fibroblasts, say researchers.

8 Aug 2012

Chk1 gene alone is sufficient to kill cancer cells

Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs.

1 Aug 2012

Biomimetic bioartificial livers and cell toxicity assays: an interview with Dr. Joris Braspenning, CEO Medicyte

Biomimetic bioartificial livers are liver organoids based on synthetic equivalents of the human extracellular matrix (ECM) which will be seeded with human cells.

1 Aug 2012

FDA accepts Exelixis’ cabozantinib NDA for filing

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

30 Jul 2012

Hypoxic lung environment increases HIF-2a tumor growth signaling

In addition to the well-known risk factor of smoking, chronic obstructive pulmonary disease (COPD) increases lung cancer risk.

25 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012